Teva Pharmaceutical Industries
TEVAAlgoritmens signaler
- ›Starkt 3m-momentum (+22.1%)
- ›Starkt 12m-momentum (+105.1%)
- ›Pris över MA50 och MA200 (uppåttrend)
- ›+109% från 52v-botten
- ›Ökad handelsvolym (+31%)
📰 Senaste nyheter & analys
Källor: Placera, Nyhetsbyrån Direkt, Google NewsTeva stock hits 52-week high at $42.04 - Investing.com
1 d sedanTeva stock hits 52-week high at $42.04 Investing.com
Investing.comTeva Pharmaceutical Industries Limited (TEVA) stock price, news, quote and history - Yahoo Finance Singapore
2 d sedanTeva Pharmaceutical Industries Limited (TEVA) stock price, news, quote and history Yahoo Finance Singapore
Yahoo Finance SingaporeTeva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline
4 d sedanBXCL501, a dexmedetomidine sublingual film, is under FDA review for first-ever at-home use for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults Acqu
Teva Pharmaceutical IndustriesGlobeNewswireUEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn’s Disease
2026-10-20In UC, duvakitug maintained high rates of clinical remission, clinical response, and endoscopic improvement at Week 44 In CD, duvakitug maintained high rates of endoscopic response, clinical response,
Teva Pharmaceutical IndustriesGlobeNewswireTeva to Host R&D Day on Wednesday, November 11 in New York City
2026-10-12TEL AVIV, Israel, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will host an R&D Day on Wednesday, November 11, 2026. At the R&D D
Teva Pharmaceutical IndustriesGlobeNewswireTeva får FDA-godkännande för schizofreniläkemedlet Weltruza
2026-10-09Världens största generikatillverkare Teva har fått amerikanska läkemedelsmyndigheten FDA:s godkännande för Weltruza (olanzapin), den första långverkande olanzapininjektionen som ges under huden en gån
Teva Pharmaceutical IndustriesFinwireTeva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia
2026-10-09WELTRUZA™ (olanzapine) for extended-release injectable suspension is the first and only once-monthly subcutaneous long-acting injectable (LAI) formulation of olanzapine for the treatment of schizophre
Teva Pharmaceutical IndustriesGlobeNewswireTeva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome
2026-10-02Based on a post hoc analysis, a majority of participants (~70%) experienced clinically meaningful tic reduction within 8 weeks of starting ecopipam An interim 18-month analysis of an ongoing open-labe
Teva Pharmaceutical IndustriesGlobeNewswireJournal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients
2026-10-02The published review examines dopamine’s role in tic generation and how approved and investigational drugs may affect dopamine to reduce tics as well as synthesizes clinical trial evidence that ecopip
Teva Pharmaceutical IndustriesGlobeNewswireSamsung Bioepis och Teva ingår globalt biosimilaravtal
2026-10-01Samsung Bioepis och Teva har ingått ett globalt licens-, utvecklings- och kommersialiseringsavtal för upp till sex potentiella biosimilarer. Två kandidater är bekräftade: SB41, med Fasenra som referen
Teva Pharmaceutical IndustriesFinwireTAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness
2026-09-30TEL AVIV, Israel, Sept. 30, 2026 (GLOBE NEWSWIRE) -- TAPI (Technology & API Services) today announced the appointment of Serge Rogasik as its Chief Executive Officer. Mr. Rogasik will lead a global bu
Teva Pharmaceutical IndustriesGlobeNewswireTeva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)
2026-09-28DEGEVMA™ is now FDA-approved across all indications of the reference product, Xgeva® (denosumab), to help prevent bone complications in adults with advanced cancer that has spread to the bone, for the
Teva Pharmaceutical IndustriesGlobeNewswireTeva Releases Q3 2026 Aide Memoire
2026-09-23TEL AVIV, Israel and PARSIPPANY, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q3 2026 Aide Memoire is available on the “I
Teva Pharmaceutical IndustriesGlobeNewswireTeva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET
2026-09-23TEL AVIV, Israel and PARSIPPANY, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quar
Teva Pharmaceutical IndustriesGlobeNewswireNew Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
2026-09-18New data revealed that healthcare providers prioritize drowsiness risk, duration of available data demonstrating long-term response and drug-drug interaction profile when selecting a treatment for tar
Teva Pharmaceutical IndustriesGlobeNewswireTeva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs
2026-09-18New findings show favorable treatment continuity for UZEDY compared to other long-acting injectables in schizophrenia, as well as oral antipsychotics in bipolar I disorder (BD-I) The new real-world da
Teva Pharmaceutical IndustriesGlobeNewswire
Klicket på "Köp i Nordnet" öppnar din Nordnet-app om installerad — där loggar du in med BankID. Annars öppnas Nordnets webbsajt där du kan logga in med BankID på samma sätt.